The Latest Breaking News from Biogen

The Federal Trade Commission (FTC) and the Securities and Exchange Commission (SEC) have launched two separate investigations into Biogen Inc (NASDAQ: BIIB) and its Alzheimer's med, Aduhelm (aducanumab).

Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings:

Biogen Inc (NASDAQ: BIIB) is trading lower Thursday morning after the company announced worse-than-expected fourth-quarter earnings results and issued guidance below estimates.

Biogen expects “minimal” revenue this year from its Alzheimer’s treatment initially hailed as potentially a breakthrough drug, but one with an eye-popping price tag that drew immediate criticism from  doctors and patient advocates

  Biogen (NASDAQ:BIIB) reported its Q4 earnings results on Thursday, February 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Biogen (NASDAQ:BIIB) is set to give its latest quarterly earnings report on Thursday, 2022-02-03. Here's what investors need to know before the announcement. Analysts estimate that Biogen will likely report an Earnings Per Share (EPS) of $3.40.

Biogen Inc (NASDAQ: BIIB) has 

Here's a roundup of top developments in the biotech space over the last 24 hours:

Biogen Inc (NASDAQ: BIIB) is selling its stake in a pharmaceutical joint venture with the South Korean conglomerate Samsung for $2.3 billion.